Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imetelstat maintenance in advanced NSCLC
NCT01137968Phase 2Completed
- Sponsor
- Geron Corporation
- Start
- May 2010
- Primary completion
- Sep 2013
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 3
01
Overview
A Phase 2 trial of imetelstat in non-small cell lung cancer (NSCLC), sponsored by Geron Corporation. Started May 2010; status: completed.
02
Drugs
imetelstat
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01137968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01137968.